Having trouble accessing articles? Reset your cache.

Imprime PGG: Additional Phase Ib/IIa data

A retrospective subgroup analysis of 11 patients with wild-type K-Ras mCRC from the second arm of an open-label, dose-escalation Phase Ib/IIa trial showed that 2, 4

Read the full 264 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE